Title: Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial

Results

1

2

3

6

7

12

14

15

24

26

27

28

29

- **Authors**: Girish Harinath^{1,2}, Virginia Lee^{1,2}, Andy Nyquist¹, Mauricio Moel¹, Jesper Hagemeier¹, 4
- 5 Stefanie L. Morgan^{1,2,*}, Anar Isman¹, Sajad Zalzala¹
 - **Affiliations:**
- 8 ^{1.} AgelessRx, Ann Arbor MI, USA
- 9 ^{2.} Division of Research and Applied Sciences, AgelessRx, Ann Arbor MI, USA
- 10 3. Data and Analytics Division, AgelessRx, Ann Arbor MI, USA
- 11 * Corresponding author
- 13 Corresponding author: Stefanie L Morgan, stefanie@agelessrx.com
- 16 but clinical data on its gerotherapeutic effects in humans remains limited. We performed a 48-17 week double-blinded, randomized, and placebo-controlled decentralized study (Participatory 18 Evaluation of Aging with Rapamycin for Longevity [PEARL]; NCT04488601; registration date 19 2020-07-28) to evaluate the safety and efficacy of rapamycin in mitigating clinical signs of aging 20 in a normative aging cohort. Participants received 5 or 10 mg / week of compounded 21 rapamycin, or placebo for 48 weeks. Safety, adverse events (AEs) and blood biomarkers were 22 collected. Efficacy was assessed using DEXA scan-based measures and standardized surveys 23 assessing quality of life (QoL) and frailty. We did not detect significant differences in safety

Abstract: Rapamycin has been shown to have longevity-enhancing effects in murine models,

25 placebo after 48 weeks. We detected dose-dependent (10 mg group) and sex-specific

improvements in lean tissue mass, pain, social functioning, overall QoL, and overall

osteoarthritis score in females, and in bone mineral content in men. Additionally, some

individuals receiving rapamycin experienced significant improvements in body composition

blood biomarkers, or moderate to severe AEs between the rapamycin treatment groups and

metrics that were associated with beneficial changes in gut health and lipid metabolism. We

conclude that low-dose, intermittent rapamycin administration over the course of 48 weeks is safe and induces sex-specific improvements in multiple aspects of healthspan, with the most robust improvements in lean tissue mass in women taking 10 mg rapamycin/week. Future work will aim to identify biometric signatures of clinical effectiveness to inform personalized treatment strategies that more broadly maximize efficacy and minimize side effects.

Keywords: rapamycin, aging, healthspan, longevity

Introduction

Aging is the biggest risk factor for all major chronic diseases, accounting for nearly 70% of human mortality [1-3]. While advancements in medical technologies and public health practices over the past 150 years have led to longer lifespans less shaped by natural selection, the period of disease and disability-free life often referred to as "healthspan" has not kept pace [4]. In conjunction with an epidemic of poor lifestyle habits, this has collectively led to a growing chasm between lifespan and healthspan known as the healthspan gap, which in the United States lasts several decades and is characterized by a high burden of functional disability and age-related diseases (such as type 2 diabetes, osteoarthritis, and Alzheimer's) that often coexist as multi-morbidities [5]. While significant research has historically focused on treating these diseases individually, a growing body of work within translational geroscience explores developing gerotherapeutics that slow the aging process and delay the onset or prevent age-related disease altogether [6].

The field of translational geroscience has made rapid advancements in recent years, due in large part to strategic utilization of interventions already approved for other conditions by the US Food and Drug Administration (FDA) [7]. By repurposing such drugs for their potential to target the biology of aging and extend healthy longevity, clinical validation is fast-tracked to permit more immediate collection of application-specific efficacy data. Notable among these is rapamycin, which is widely used for its purported longevity and healthspan benefits within the pro-longevity community [8]. While evidence supports a role for rapamycin in improving lifeand healthspans in preclinical studies [9], little data exists on its clinical efficacy in normative aging humans.

As an FDA-approved small molecule drug, rapamycin is an evolutionarily conserved inhibitor of the mammalian target of rapamycin serine/threonine kinase complex 1 (mTORc1), a known regulator of aging processes [10, 11]. Hyperactivity of mTORC1 has been linked to multiple chronic disease processes in nearly every organ system, while mTORC1 inhibition induced by caloric restriction and rapamycin or its derivatives (rapalogs) has been shown to reliably extend lifespan and healthspan across organisms from yeast to non-human primates [12-21]. Rapamycin-mediated mTORC1 inhibition has demonstrated particular efficacy as a

geroprotective intervention in mice, extending lifespan in heterogeneous genetic backgrounds across multiple studies from independent labs at multiple dosages, dosing periods, and regimens, even in elderly animals [14, 16, 18, 21, 22].

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

While rapamycin has demonstrated a more pronounced lifespan-enhancing effect in female than male mice, mitigation or reversal of age-associated changes in multiple organ tissues and the immune system have been observed for both sexes [23-25]. These findings have been reproduced in companion dogs and marmosets, however, clinical data on rapamycin's gerotherapeutic effects in humans remains limited [9, 12, 17, 26]. Given the substantial promise in preclinical data, it is essential to obtain a deeper understanding and clearly define the clinical benefits of rapamycin use for improving healthy aging in the generally healthy, adult population. In particular, it will be important to understand how rapamycin may impact the phenotypes of the biological aging process that substantially increases the risk of age-related disease and mortality, such as an accumulation of visceral adipose tissue (VAT) and a loss of lean muscle tissue and bone mass [27-32]. These are some of the most salient and functionally consequential measures of biological aging, which frequently lead to reduced quality of life (QoL), increased pain, and limited mobility, particularly for post-menopausal women [33, 34]. Collectively, this contributes to the marked decline in health that often occurs during this time period [33]. It has been suggested that use of low-dose rapamycin may mitigate these features of the aging process, enhancing healthspan [25, 35, 36].

Widespread adoption of rapamycin as a gerotherapeutic has historically been limited by concerns regarding its known impact on immunosuppression, hyperlipidemia, and hyperglycemia [37]. However, the vast majority of these effects stem from high, chronically administered doses utilized in severely ill organ transplant or cancer patients, where the clinical aim is inhibition of the immune system or anti-tumorigenic effects. In contrast, as a gerotherapeutic for normative aging populations, low-dose, intermittent rapamycin is revealing promise for minimizing side effects while still mitigating aspects of age-related decline [38-40]. For example, Mannick *et al.* demonstrated that healthy elderly individuals taking 0.5 mg of a rapalog daily or 5 mg/ week for 6 weeks mitigated age-related immune decline by enhancing the adaptive immune system's response to vaccination [41]. This supports our recent findings

from a study of 333 low-dose rapamycin users indicating a high perceived QoL and improved health outcomes compared to non-users [8]. Preliminary data suggest that these effects stem from a partial inhibition of mTORc1 in low-dose rapamycin (rather than the complete inhibition observed at higher doses), which has been demonstrated to mitigate age-related decline by stimulating autophagy, reducing senescent burden, and reducing pro-inflammatory cytokines that drive chronic inflammation [9, 15, 24, 42, 43]. While promising findings such as these have encouraged some physicians to prescribe off-label rapamycin as a therapy to maintain healthspan, there are many open questions that require further study, particularly in a clinical setting.

An important gap in the clinical understanding of rapamycin for longevity is that to date, no long-term randomized controlled trials (RCT) have been conducted to explore low-dose, intermittent rapamycin regimens for improving multiple healthspan metrics in normative aging cohorts. The current study, the Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial, aimed to address this gap. PEARL represents the largest and longest clinical study of rapamycin use for healthy aging performed to date. This 48-week double-blinded, randomized placebo-controlled decentralized study evaluated the safety and efficacy of rapamycin in mitigating clinical signs of aging in a generally healthy cohort. Here, we present the first evidence to date, to our knowledge, that low-dose rapamycin administration is safe over the course of 48 weeks and induces sex-specific improvements in lean muscle mass, bone mineral content, aspects of age-related frailty, and overall QoL. Further, we highlight additional benefits observed specifically in rapamycin responders that may offer mechanistic insights into key biological drivers of clinical effectiveness that will be investigated in greater depth in future studies.

Methods

Study design

The PEARL study was a decentralized, single-center, prospective, double-blind, placebo-controlled trial assessing rapamycin in healthy individuals aged 50-85 years, to determine the safety and efficacy in mitigating aging-related decline (**Supplementary Figure S1**).

The study was conducted in accordance with the standards of Good Clinical Practice, as defined by the International Conference on Harmonisation and all applicable federal and local regulations. The study protocol was approved by the institutional review board of the Institute of Regenerative and Cellular Medicine in May 2020 (IRCM; approval number IRCM-2020-252).

Study endpoints

The primary endpoints of this study included safety, which included the collection of adverse events (AEs), safety blood biomarkers, and visceral adiposity. Secondary endpoints included efficacy blood biomarkers, DEXA scan-determined lean tissue mass and bone mineral content, and standardized surveys assessing quality of life and frailty.

Study population

Participants were recruited via the AgelessRx online medical platform. Patients were screened for eligibility, and if deemed eligible, informed consent was obtained for participation in the study.

Participants were eligible for the study if they were aged between 50 and 85 years at the start of the study, were interested in taking rapamycin off-label, were willing to undergo minimally invasive tests, and were in good health or had well-managed clinically-stable chronic diseases. Participants were excluded from the study if they had anemia, neutropenia, or thrombocytopenia, were premenopausal, were scheduled to undergo major surgery in next 12 months, were undergoing or were scheduled to undergo chemotherapy, were scheduled for immunosuppressant therapy for an organ transplant, had impaired wound healing or history of chronic open wound, untreated dyslipidemia, impaired hepatic function, chronic infections requiring ongoing treatment or monitoring (e.g. human immunodeficiency virus/acquired immunodeficiency syndrome, chronic Lyme disease), allergy to rapamycin, clinically-relevant primary or secondary immune dysfunction or deficiency, chronic oral corticosteroid or immunosuppressant medication use, fibromyalgia, chronic fatigue syndrome/myalgic encephalitis, breast implant illness, congestive heart failure, impaired renal function, poorly

controlled diabetes, type I or insulin-dependent type II diabetes, untreated or treated within the last five years for substance abuse disorder, and untreated or poorly controlled mental health disorder. Further, those who had taken metformin, rapamycin, or rapalogs were excluded unless the participant agreed to a 6 month washout period prior to the start of the trial.

Treatments

Study participants were randomized into three groups: receiving 5 mg of rapamycin, 10 mg of rapamycin, or placebo, once per week. Placebo capsules were compounded to look similar and were taken orally (Belmar Pharma Solutions (Golden, CO, USA)). Study participants were prescribed the drug for 48 weeks upon enrollment in the study and were dispensed supplies for 12 weeks at a time.

Assessments

All assessments were performed at baseline, after 24 weeks, and after 48 weeks of rapamycin treatment. Blood testing was performed two additional times, at 2 weeks and 4 weeks of treatment, to evaluate safety. All blood testing was performed by local Quest Diagnostics of LabCorp laboratories, and included complete blood count (CBC), comprehensive metabolic panel, liver function tests, renal function tests, and lipid panels. DEXA body composition scans were performed primarily by DexaFit or Fitnescity locations, based on local availability, though some participants utilized third party locations based on site availability. Regardless of site, the outcome measures obtained by DEXA scans were body mass index (BMI), visceral fat, bone mineral content, bone mineral density, and lean tissue mass. Gut health was evaluated using the Thorne Gut Health test.

Summary health scores were calculated as a sum of responses on baseline survey responses of health for questions of frequency of use of smoking, consuming caffeinated beverages, consuming alcoholic beverages, eating sugary, salty, or "junk" foods, exercise (vigorous and moderate intensity), and weight. Benefit Score was calculated by ranking the percent change on each DEXA measure evenly into high, medium, and low benefit, and

summing scores into a meta score. VAT measures were reverse-scored, as decrease in VAT raw values corresponds with improvement on this measure. The summary meta score was then again divided evenly into a high, medium, and low ranking. High scores were considered "improved", and low scores were considered "decline", while in-between scores were considered "stasis".

Health-related QoL was assessed by the short-form 36 (SF-36) survey, which consists of 36 questions covering eight health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality (energy levels), social functioning, role limitations due to emotional problems, and emotional health [44]. The responses are scored and summarized to provide a profile of an individual's perceived health status. Pain, fitness, and functional limitations were assessed using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index, which is a questionnaire that is commonly used to assess the health status of individuals with osteoarthritis of the hip and knee [45]. It consists of 24 items divided into three subscales: pain, stiffness, and physical function. The responses are scored to provide quantitative assessments of the severity of symptoms and functional limitations associated with osteoarthritis.

Adverse Events

Adverse events (AEs) were obtained through weekly monitoring forms sent out to participants. Clinical trial staff reviewed and documented AEs. Both expected (already known) and unexpected AEs were reported and documented. A full list is presented in **Table 2**.

Statistical analyses

All initial analyses were performed by researchers blinded to the study treatment. Demographic and baseline characteristics were summarized using descriptive statistics. All data were tested for normality using visual inspection of histograms and Q-Q plots, and Shapiro-Wilks tests were performed. Data were summarized using mean and standard deviation (SD) and where appropriate, counts and percentages were reported. Baseline data were compared between the three treatment arms using Analysis of Variance (ANOVA), independent t-test or

 χ^2 test. To compare the difference in mean change from baseline to most recent follow-up (48 weeks) between treatment arms, we employed ANOVA and BMI-adjusted marginal mixed-effect models. Following this, full age-, sex-, and BMI-adjusted linear mixed-effects models with a repeated measures structure were conducted. Interaction terms (time by treatment arm, as well as time by treatment arm by sex) were included to investigate group and gender effects and their trajectory over time. Where appropriate, stratified post-hoc analyses were conducted within sex and between treatment arms (10 mg vs. placebo and 5 mg vs. placebo). All analyses were conducted using SPSS 28 (IBM, Armonk, NY, USA) and Python 3.10 (Python Software Foundation). A p-value of p<0.05 was considered significant.

Results

Participant demographics

A total of 115 participants were included in this study, of whom 40 received 5 mg/week of rapamycin, 36 received 10 mg/week of rapamycin, and 39 received placebo (**Supplementary Fig S1a**). At baseline, all participant groups were comparable across measures of age, sex, height, weight, BMI, and blood safety markers, with the exception of the mean HbA1C, which was lower in the 5 mg group than placebo (5mg mean = 5.2%, SD = 0.2; placebo mean = 5.3%, SD = 0.3; t(72)=2.556, p=0.013; **Table 1**). Overall, participants were in exceptionally good health at baseline, as evaluated by self-reports of health (**Supplementary Fig S1b**).

Safety: Adverse events

AEs were collected throughout the study as reported by participants on periodic surveys or through direct contact with investigators (**Supplementary Fig 2a**; see **Table 2** for all AEs). The most commonly reported AEs were cold/flu/sinus symptoms, musculoskeletal pain, mouth sores, and malaise, with a greater number of AEs reported in the placebo group relative to treatment conditions (**Supplementary Fig 2b, Table 2**). The most commonly reported rapamycin specific AEs were gastrointestinal issues. Surprisingly, mouth sores, which are often associated with rapamycin treatment [46], were most frequently reported in the placebo group

(placebo: n=27, 5 mg: n=4, 10 mg: n=14; **Table 2**), though the same number of individuals reported mouth sores in the 10 mg and placebo group (n=6).

Notably, throughout the length of the trial, participants in the rapamycin treatment groups reported increased instances of improvements in chronic ailments (chronic issue flare) that were present when they first entered the trial compared to placebo (placebo: n = 14, 5 mg: n = 24, 10 mg: n = 28). Conversely, participants in the placebo group reported increased instances of worsening of their chronic ailments (chronic issue severity) compared to treatment groups (placebo: n = 12, 5 mg: n = 4, 10 mg: n = 6; **Table 2**). No significant safety-related issues were detected in the blood work results of any participants during periodic check-ins, or after the 48 week study period for the 105 participants who completed the entirety of the study (**Supplementary Table S1**).

Of the 123 total participants enrolled in the study, Serious AEs (SAEs) were reported for four rapamycin users (three in 5mg group and one in 10mg group) and two placebo users. Specifically, in the 5 mg group, one participant was hospitalized during the study period due to respiratory symptoms that seemed related to anemia, which resolved with a blood transfusion. A second participant in the 5 mg group had a severe infection requiring treatment from their healthcare provider, which resolved after medication use (prednisone, doxycycline, and albuterol). The third participant in the 5mg group had a hamstring tear prior to the study, that healed slowly during the trial. In the 10mg group, a participant reported a sore throat, but tested positive for group A strep and was prescribed amoxicillin, which resolved the symptoms. One participant in the placebo group died of myocardial infarction during the study period. A second participant in the placebo group reported a stomach virus that required attention from a medical provider, and was diagnosed with small urinary infection. Symptoms resolved after treatment.

While not an intended endpoint for this study, the study period was during the COVID-19 pandemic, and a confirmed COVID-19 infection was reported for 25 participants: 10 in the placebo group (29%), 8 in the 5 mg treatment group (21%), and 7 in the 10 mg treatment group (21%). Among these, no differences in infection rates, symptom severity, duration of illness, or

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

length of recovery were noted between groups. Importantly, those with SAEs (described above) were not noted to have COVID-19 upon physician testing. Efficacy of rapamycin on healthspan metrics **DEXA Scan results** Participants underwent DEXA scans to assess visceral adipose tissue (VAT) mass, bone mineral content (BMC), and lean tissue mass (LTM) at three timepoints (baseline, 24, and 48 weeks of treatment) to explore the effects of rapamycin on measures crucial for healthy aging and the prevention of frailty and disease. At baseline, VAT mass, BMC, and LTM were similar between the three treatment groups (Supplementary Table S2). Over the study period, VAT mass increased most in the placebo group (mean = +35.34 g, SD = 290.76 g) and decreased in the group taking 5 mg rapamycin (mean = -39.85 g, SD = 185.18 g), while BMC and LTM increased only in the 10 mg rapamycin treatment group (BMC: mean = +19.41 g, SD = 104.34; LTM = 517.87 g, SD = 2440.18). While notable trends of change in body composition measures from baseline to 48 weeks were observed between treatment groups, none were statistically significant (linear mixed-effects models interaction: VAT: F(2, 101.408) = 0.978, p=0.379; BMC: F(2,104.415) = 1.403, p=0.250; LTM: F(2,126.996) = 1.115, p=0.331; BMD: F(2,166.294) = 1.596, p=0.552) (Figure 1a, Supplementary Table S2). While some changes to some body composition metrics (e.g. visceral adipose) in rapamycin treatment groups were observed at 24 weeks, these effects stabilized to measures reported for 48 weeks by the end of the trial (Supplementary Fig S3a, Supplementary Table S2). As rapamycin has been suggested to have differential effects in males and females, we explored this possibility by evaluating changes in DEXA scan data across sex (Table 3). Analysis with linear mixed-effects models revealed statistically significant differences in BMC change between groups across sex (interaction F(2, 193.245) = 4.489, p = 0.012, Table 3), which subsequent analysis revealed was specifically driven by improvements in the male 10 mg rapamycin treatment group vs placebo (interaction F(1, 129.224) = 4.563, p = 0.035, (Figure 1b). This was consistent with changes of bone mineral density (interaction F(1, 131.924) = 4.956, p =.028).

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

Similarly, statistically significant differences in LTM were observed between groups when assessed across sex (F(2, 206.447) = 5.439, p = 0.005, Table 3), which subsequent analyses revealed were primarily driven by differences between sex in the 10mg rapamycin treatment group (F(1, 134.554) = 8.880, p = 0.003, Figure 1c). Post-hoc within sex analyses confirmed that gains in LTM over 48 weeks were distinct to female participants taking 10 mg rapamycin compared to placebo (female 10mg = +1,939.7g (SD = 1,998.9) versus female placebo = -298.1g (SD = 1,191.1); F(2, 41.242) = 6.423; $\beta = 55.5$, SE = 16.9, p = 0.002). This highlights that the average improvement in LTM in female participants was particularly robust at an estimated rate of 55.5g per week faster than those on placebo. No significant changes in BMC and LTM were observed in all other groups, nor were any significant changes in VAT observed upon subsequent analyses (Supplementary Fig S3b). Notably, marked variability in measures of VAT, LMT, and BMC was observed for all rapamycin users independent of dose (Table 3, Supplementary Table S2). This resulted in dramatically different impacts for the highest and lowest responding individuals across all measures for both males and females (Supplementary Figure S4). Exploration of raw values of response for individual participants revealed categories of individuals with improvement and decline for each body composition measure (Supplementary Table S2, Figure 2a). Comparing across groups, we observed that a greater percentage of individuals in the improvement group were rapamycin users, with no specific bias in response across all measures by sex (Figure 2b, c). Upon further investigation of individual body composition measures, sex-agnostic rapamycin associated improvement held true for VAT (Figure 2d), however, the percent of participants showing improvement in BMC and LTM differed by gender (Figure 2e, f). This is particularly notable for BMC, where two thirds of 10mg males showed improvement (Figure 2e), and in LTM, where all of the 10mg female participants demonstrated improvements (Figure 2f). Upon further investigation, we noted that improvements in VAT correlated with improvements on BMC and LTM, as well as with improved weight and BMI (Figure 3a). Given these findings, we computed a "Benefit Score" for users based on summary scores of improvement or decline on each body composition measure evaluated by DEXA.

Benefit score was significantly associated with rapamycin use (t(44.41) = 2.175, p = 0.035),

though some placebo users also saw global improvements and subsequently high Benefit Scores (**Figure 3b**). As our bioavailability study has previously suggested a 3.5x reduction in potency for compounded rapamycin relative to generic, we reasoned that the 10mg group was more likely to be in a relevant bioavailable therapeutic dose range, and thus further investigated Benefit Score in the 10mg vs Placebo groups to explore what might be driving differences in rapamycin response. Importantly, separation of Benefit Scores by rapamycin dose and sex in this manner revealed a pronounced female benefit bias, with all female rapamycin users showing only improvement on the Benefit Score (**Figure 3c**). Subsequent analysis of gut health and blood biomarkers by benefit score revealed significant changes in measures of gut dysbiosis (F(2,54) = 3.215, p = 0.04; t(54) = -2.150, p = 0.036), immune readiness (F(2,54) = 3.157, p = 0.05; t(54) = 2.517, p = 0.015; **Figure 3d**), and LDL levels (F(2,102) = 4.262, p = 0.017; t(74) = -2.505, p = 0.014; **Figure 3e**) between high and low Benefit Scores, with rapamycin users showing greater magnitude of beneficial change than placebo.

Blood Biomarkers

In addition to completing routine blood work for safety monitoring, blood biomarkers of health, such as LDL, hemoglobinA1c, triglycerides, and insulin levels were collected throughout the study. While there were no significant differences between groups in biomarkers that were outside the healthy reference range after 48 weeks, significant differences between treatment and control groups were observed for mean change in corpuscular hemoglobin (MCH: 5mg: -0.1 (0.9), 10mg: -0.4 (1.1), Placebo: 0.2 (1.2); F(2, 101) = 3.232, p = 0.040) and mean platelet volume (MPV: 5mg: -0.1 (0.4), 10mg: -0.1 (0.4), Placebo: 0.1 (0.4); F(2, 101 = 4.802, p = 0.10). Post-hoc testing between treatment group pairs revealed additional changes for participants in the 10 mg rapamycin treatment group in chloride levels (10mg: +0.6 (1.5), Placebo: -0.3 (2.0); t(65) = 2.125, p = 0.037), carbon dioxide levels (10mg: -1.2 (1.8), Placebo: -0.4 (2.2); t(65) = 1.786, p = 0.079), and mean corpuscular volume (MCV: 10mg: -1.0 (2.2), Placebo: 0.4 (2.8); t(65) = 2.258, p = 0.027), and patients in the 5 mg rapamycin treatment group in platelets (Supplementary Figure S5a-b, Supplementary Table S1). Stratifying by sex did not reveal any additional patterns of significant change between dosing groups and controls over time.

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

Quality of life Evaluation of rapamycin's effects on self-reported quality of life (QoL) was conducted using the SF-36 scale. Baseline measures revealed generally high QoL scores across the study cohort, with no notable significant differences between groups (overall QoL scores of 83.7 (10.4), 88.1 (7.0), and 84.5 (12.0) for the 5 mg, 10 mg, and placebo groups, respectively, (F(2, 110) = 1.987, p = 0.142; Supplementary Table S3). After 48 weeks of treatment most SF-36 scores improved in all groups, however, with the exception of general health (5mg: +5.6 (10.3), 10mg: +3.2 (10.0, Placebo: +0.8 (12.0); F(2, 87) = 4.488, p = 0.014), no statistically significant changes were detected using marginal linear mixed-effect models between treatment groups across time (Supplementary Figure S6a, Supplementary Table S3). As we observed sex-specific differences in DEXA measures, we similarly evaluated whether QoL measures differed across sex between the treatment groups over time (mean QoL scores stratified by sex are presented in **Table 4**). Linear mixed-effect models were employed to further explore the interaction of sex and treatment groups with change in QoL over time. Significant longitudinal differences in pain between groups and sex were observed (interaction F(2, 201.308) = 6.815, p = 0.001), which was driven by a sex difference specifically in the 10 mg rapamycin treatment group (10mg vs Placebo: F(1, 130.926) = 16.403, p < 0.001, Figure 4a,b). This was confirmed in post-hoc analysis, where specifically females taking 10 mg rapamycin (+14.7 SD = 13.9) saw improvements in pain compared to placebo (β = 0.332, SE = 0.110, F(1, 6.928) = 9.121, p = 0.020), indicating that similar to gains in LTM, among females, improvements in pain are another robust effect of 48 weeks of rapamycin treatment. Within the 10 mg rapamycin treatment group, the rate of improvement in social functioning and overall quality of life also showed group and sex differences (Supplementary **Table S3**), with both social functioning (+12.5 SD = 24.1) and QoL (+5.8 SD = 4.6) improving most in the 10mg female group (group by sex interaction F(2, 188.862) = 2.701, p = 0.070 and F(2, 200.291) = 2.028, p = 0.134, respectively). When limiting analyses to 10mg compared to the placebo group, differences in the rate of improvements in social functioning and quality of life between group and sex reached significance (interaction F(1, 132.742) = 5.551, p = 0.020 and

F(1, 123.268) = 6.753, p = 0.010, respectively), which, as with pain, appeared to be specifically driven by females within the 10 mg rapamycin treatment group (**Figure 4a,b**).

Frailty

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

Finally, we measured symptoms of osteoarthritis (OA) using the WOMAC survey as a marker for frailty, another important factor defining the length of an individual's healthspan. Baseline scores were not significantly different across groups (Supplementary Table S3), and linear mixed-effects models again revealed no significant patterns of change in scores across all groups over the 48-week study period (Supplementary Figure S6b). However, given previous sex-specific effects in other outcome measures, analyses of WOMAC scores were repeated by exploring differences across sex and groups (Table 4). This revealed statistically significant differences in the WOMAC pain score between groups and sex (interaction F(2, 194.531) = 3.516, p=0.032), with improvements observed particularly for female participants in the 5 mg and 10 mg rapamycin group (-0.9 SD = 1.8; -0.8 SD = 2.9, respectively; Figure 4c,d), and trends of improvement for the overall frailty score in the same groups (Supplementary Table S3; group by sex interaction F(2, 202.257) = 2.172, p = .117). Evaluation of changes across sex limited to the 10 mg rapamycin group versus placebo revealed a significant improvement in both measures (interaction F(1, 120.251) = 5.791, p = 0.018 and F(1, 111.480) = 5.925, p =0.017, respectively). This highlights that once again, female participants in the 10 mg group appear to improve most (Figure 4c,d). No other significant differences were observed for this measure.

Discussion

Few clinical trials to date have evaluated the effects of rapamycin and its derivatives in generally healthy individuals, and those that have been conducted are often challenged by a small cohort size, short-term follow-up, or both. While the most robust of these studies have suggested improvements in age-related immune decline in healthy elderly individuals administered low-dose everolimus for 6 to 16 weeks [41], no study to date has definitively demonstrated the efficacy of rapamycin for supporting healthy aging in normative aging

individuals. The PEARL trial represents one of the most robust and comprehensive efforts evaluating the long-term safety and efficacy of low-dose rapamycin for addressing multiple aspects of age-related decline in a normative aging cohort.

In the current study, no significant differences in markers of metabolic health, liver, and kidney function, or moderate to severe AEs in the rapamycin treatment groups were reported compared to placebo after 48 weeks. This is consistent with previous reports summarized in a review by Maier's group that healthy individuals are not likely to experience serious side effects from low dose rapamycin, and suggests that concerns over negative effects of rapamycin stemming from studies of high-dose, daily usage in chronically ill individuals may have limited applicability in the context of rapamycin use for healthy aging [47]. Indeed, we observed more instances of individuals reporting improvements in chronic ailments in the rapamycin treatment groups than in placebo, and more instances reported of worsening ailments in the placebo group compared to treatment groups after 48 weeks. This effect will be important to investigate further in longitudinal follow-up with PEARL participants.

While among PEARL participants, those taking 10 mg of rapamycin per week did initially report more gastrointestinal and neurological AEs (e.g. diarrhea and headaches) compared to those taking placebo, all (except for one) were acute AEs that resolved on their own, or were not severe enough to prevent continuation of the rapamycin regimen. Interestingly, despite well-known impacts of rapamycin on causing mouth sores and a strong association with its bioavailability and potency [46, 48], participants in the placebo group reported increased incidents of mouth sores than those in either of the treatment groups, despite the same number of individuals reporting mouth sores in the 10 mg rapamycin group and placebo (n = 6). This may be a unique property of compounded rapamycin, though follow-up studies are currently underway to understand this more comprehensively.

Of note, the PEARL trial was ongoing during the COVID-19 pandemic and rapamycin has been associated with favorable outcomes in response to SARS-CoV2 [8, 49, 50]. Consistent with this, we did observe a decreased incidence of COVID-19 reports in the rapamycin treatment groups (19.7%) compared to placebo (25.6%). Clinical trials are underway that are specifically

designed to more robustly evaluate the efficacy of rapamycin and its derivatives on COVID outcomes [28-32, 51].

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

Over the 48 weeks of the study, weekly rapamycin use demonstrated dose-dependent and sex-specific improvements in multiple functional healthspan metrics compared to placebo, including lean tissue mass, bone mineral content, pain (SF-36, WOMAC), social functioning (SF-36), overall quality of life (SF-36), and overall osteoarthritis (WOMAC) score. All statistically significant benefits were observed in participants taking 10 mg rapamycin per week and consistent with preclinical reports of a female-benefit bias in mice, female participants demonstrated significant benefits across all the outcome measures except bone mineral content [14, 18]. Notably, the most robust improvements observed after 48 weeks were increases in lean muscle mass within this group. However, as all groups of rapamycin users (across gender and dose) had individuals that showed large improvements in body composition measures over time, a summary improvement score accounting for improvement or decline across all DEXA body composition measures was computed as a Benefit Score. Importantly, all women taking 10mg of rapamycin had improvements on the Benefit Score, and showed no declines, whereas men were represented in both groups. Across all participants, those with high benefit scores had significant improvements in gut health measures of gut dysbiosis and immune readiness, and in LDL levels relative to those with low benefit scores. Greater responses on these measures were observed for rapamycin users than placebo users. Taken together, these findings suggest that digestive health, diet, and/or microbiome may play a significant role in rapamycin response and subsequent likelihood of benefits, and will be a focus of our future work.

Findings from this study that male participants in the 10 mg rapamycin group gained an average of 1.4% BMC over 48 weeks and female participants in the 10 mg group gained an average LTM of 4.5% hold significant promise for rapamycin in reducing risks of age-related disease and mortality. This is particularly true for the highest rapamycin responding individuals, who exhibit greater improvements in body composition than typical for individuals of this trial age cohort. For example, one female participant in the 10 mg rapamycin group exhibited a 19% improvement in lean muscle mass over the 48 week period, and another saw a 15% increase in

BMC over two years of taking rapamycin consistently during and post-trial. Given the expected worsening of body composition metrics each year after the age of 60, which have a compounding influence on the risk of age-related adverse outcomes, rapamycin clearly has an important role as a gerotherapeutic in the future of healthy longevity medicine

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

While this trial extended notably longer than other human trials of rapamycin use for healthy longevity to date, it is likely that even greater effects would be observed with an increased observation period, a broader (specifically higher) range of doses, as well as a larger study cohort. Further, while it was outside the scope of this study to determine all sources of variability, there are several lifestyle factors (such as diet, alcohol consumption, sleep quality, and activity levels) that may influence VAT, LTM, and BMC changes over time [52, 53], and which may have yet-to-be-identified impacts on rapamycin bioavailability that would add value to future studies on this topic.

Across all measures in this study, a remarkable level of variability in response was observed for all rapamycin users, regardless of dose. Given our recent work on the variability of rapamycin bioavailability in individuals, we expect that it played a meaningful role in the results observed here, though this trial concluded prior to our findings on bioavailability. Further, we have discovered since the conclusion of this trial that compounded rapamycin is approximately 3.5x less bioavailable than commercially available formulations, suggesting that the 5mg and 10mg rapamycin groups received an average equivalent of 1.4mg and 2.9mg respectively [48]. Although both doses are relatively low, making the observation of benefits in the treatment group more striking, the 10mg rapamycin cohort in this study was more firmly in the range of what is thought to be an optimal longevity dose range for rapamycin [8, 41, 47, 54]. While future studies will be necessary to draw clear conclusions on whether even higher doses lead to improved effects, we expect that this is a key factor in the often stronger and more reliable patterns of improvement seen for the 10mg rapamycin cohort relative to the 5mg cohort. We highlight this to emphasize the importance of personalized rapamycin dosing and continual routine monitoring of blood rapamycin levels in users to ensure maximal benefits, until such time as the optimal longevity dosing dynamics for rapamycin are more clearly understood.

Beyond physical measures of rapamycin impacts explored in this study, self-reported measures of perceived health and quality of life also showed improvement for all groups. This is especially important in a normative aging population, still in their healthspan, as evaluating changes in QoL captures multiple dimensions of health and functioning that both precede and go beyond disease progression alone. As maintaining an active, pain-free, high quality of life (QoL) in aging is one of the most important aspects of healthspan, findings from the current study that rapamycin users had improved scores on multiple measures of the well-established SF-36 and WOMAC scales are particularly promising. While a female-benefit bias was noted for both measures, significant improvements were observed only for the female 10mg rapamycin group. This is consistent with previous findings in a cohort of 333 adults using off-label rapamycin for healthy aging in which rapamycin was associated with increased reports of happiness, brain function, feelings of youthfulness, calm, reduced anxiety and pain compared to non-users in that same timeframe (up to 10 years for some participants) [8].

Of particular note, with PEARL, we are the first to show that 10 mg rapamycin/week for 48 weeks has a modest but significant benefit on osteoarthritis symptoms, specifically in women, based on the WOMAC clinical OA assessment. As our study was within a normative aging population, small improvements in early age-related progression of OA could lead to substantial cumulative benefits over time on frailty outcomes [55, 56]. Despite this, follow-up studies are required to determine why males did not demonstrate similar OA associated benefits in this study, and what additional adjustments or considerations would be required for men to derive similar OA related benefits.

Conclusion

The PEARL trial is the largest and longest decentralized RCT evaluating the safety and efficacy of low, intermittent "longevity doses" of rapamycin on healthy aging through the measurement of clinically relevant healthspan metrics. Our findings provide evidence that low dose, intermittent rapamycin regimens are well tolerated and do not lead to any serious adverse events or clinical abnormalities when administered for at least one year within normative aging individuals. Beyond this, we observed benefits for rapamycin users in the PEARL trial, as measured by

significant improvements in lean muscle mass, pain, social functioning, frailty outcomes, and overall quality of life in females, and improved bone mineral density in males. Further, there were some individuals in the rapamycin treatment groups that experienced large improvements in body composition metrics after 48 weeks, which were further associated with beneficial changes in gut health and LDL levels. Future work will more comprehensively explore what drives high response rates to rapamycin, and will aim to identify biometric signatures that can be used to predict clinical effectiveness and inform personalized treatment strategies.

As our previous investigation on the bioavailability of rapamycin suggests no significant differences between men and women, further investigation in to mediators of sex specific effects of rapamycin are warranted to elucidate what role factors such as differences in hormone signaling, growth factor signaling, mTOR signaling activity, genetic polymorphisms, or other factors meaningfully contribute to the sex-specific effects we observed in this study, and particularly the female-benefit bias we observed for most measures. While the current report details the primary endpoints for the PEARL trial, many PEARL participants continue to take longevity doses of rapamycin, and have consented to share ongoing information. Reports on these longitudinal studies will be released publicly as available, in keeping with our strong conviction that freely permitting combinatory result analyses will allow for better understanding of optimal dosing, safety, changes in aging biomarkers, and overlapping outcomes for this important gerotherapeutic intervention.

Collectively, the PEARL clinical trial is one of the first to provide evidence that low-dose rapamycin may be safely administered for extended periods of time and may counteract several aspects of age-related decline. Further, it represents the first study indicating dose-dependent, sex specific efficacy for rapamycin in improving healthspan metrics in humans. As such, our collective evidence suggests that well beyond merely clinical measures of health improvements, rapamycin may promote essential, comprehensive well-being associated with "adding life to years, not just years to life".

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

Statements and Declarations: *Acknowledgements* The authors would like to thank the participants who took part in this study. Financial support from our generous donors, particularly Vitalik Buterin, Micah Zoltu, Brad Armstrong, and anonymous gifts, administrative support, and article publishing charges were provided by AgelessRx. Clinical trial oversight was conducted by PHAGE corporation. We extend special thanks to Mikhail Blagosklonny, James Watson, Alan Green and Thorne for their participation and support in conducting this trial. Competing interests GH, VL, AN, MM, SM, AI, and SZ are employees and shareholders of AgelessRx. JH has received financial compensation from AgelessRx for their contributions. Author contributions Virginia Lee, Andy Nyquist, Anar Isman, and Sajad Zalzala designed and implemented the study. Girish Harinath, Jesper Hagemeier, and Stefanie Morgan performed data analysis. Girish Harinath, Virginia Lee, Andy Nyquist, Mauricio Moel, Stefanie Morgan, Anar Isman, and Sajad Zalzala wrote and edited the manuscript. All work was supervised by Stefanie Morgan, Anar Isman, and Sajad Zalzala. Corresponding author is Stefanie Morgan. References Al-Maskari F. LIFESTYLE DISEASES: An Economic Burden on the Health Services. UN 1. Chronicle [Internet]. [cited 2024 August]. Available from: https://www.un.org/en/chronicle/article/lifestyle-diseases-economic-burden-healthservices#:~:text=By%202030%2C%20the%20proportion%20of,African%20and%20Eastern%20M editerranean%20regions. 2. Ford ES, Bergmann Mm Fau - Kröger J, Kröger J Fau - Schienkiewitz A, Schienkiewitz A Fau - Weikert C, Weikert C Fau - Boeing H, Boeing H. Healthy living is the best revenge: findings

- from the European Prospective Investigation Into Cancer and Nutrition-Potsdam study. (1538-
- 586 3679 (Electronic))
- 587 3. Kvaavik E, Batty Gd Fau Ursin G, Ursin G Fau Huxley R, Huxley R Fau Gale CR, Gale
- 588 CR. Influence of individual and combined health behaviors on total and cause-specific mortality
- in men and women: the United Kingdom health and lifestyle survey. (1538-3679 (Electronic))
- 590 4. Coe E, Dewhurst M, Hartenstein L, Hextall A, Latkovic T. At least six years of higher
- quality life for everyone is within reach. Adding years to life and life to years [Internet]. 2022
- 592 [cited 2024 August]. Available from: https://www.mckinsey.com/mhi/our-insights/adding-
- 593 years-to-life-and-life-to-years.
- 594 5. Garmany A, Yamada S, Terzic A. Longevity leap: mind the healthspan gap. NPJ Regen
- 595 Med. 2021;6(1):57 https://doi.org/10.1038/s41536-021-00169-5.
- 596 6. Sierra F. The Emergence of Geroscience as an Interdisciplinary Approach to the
- 597 Enhancement of Health Span and Life Span. (2157-1422 (Electronic))
- 598 7. Kulkarni AS, Aleksic S, Berger DM, Sierra F, Kuchel GA, Barzilai N. Geroscience-guided
- repurposing of FDA-approved drugs to target aging: a proposed process and prioritization.
- 600 Aging Cell. 2022;21(4):e13596 https://doi.org/10.1111/acel.13596.
- 601 8. Kaeberlein TL, Green AS, Haddad G, Hudson J, Isman A, Nyquist A, et al. Evaluation of
- off-label rapamycin use to promote healthspan in 333 adults. Geroscience. 2023;45(5):2757-68
- 603 https://doi.org/10.1007/s11357-023-00818-1.
- 604 9. Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nat
- 605 Aging. 2023;3(6):642-60 https://doi.org/10.1038/s43587-023-00416-y.
- 606 10. Chung J, Kuo Cj Fau Crabtree GR, Crabtree Gr Fau Blenis J, Blenis J. Rapamycin-FKBP
- specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein
- 608 kinases. (0092-8674 (Print))
- 609 11. Castilho RM, Squarize Ch Fau Chodosh LA, Chodosh La Fau Williams BO, Williams Bo
- 610 Fau Gutkind JS, Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and
- 611 aging. (1875-9777 (Electronic))

- 612 12. Urfer SR, Kaeberlein TL, Mailheau S, Bergman PJ, Creevy KE, Promislow DEL, et al. A
- 613 randomized controlled trial to establish effects of short-term rapamycin treatment in 24
- 614 middle-aged companion dogs. GeroScience. 2017;39(2):117-27 10.1007/s11357-017-9972-z.
- 615 13. Robida-Stubbs S, Glover-Cutter K Fau Lamming DW, Lamming Dw Fau Mizunuma M,
- 616 Mizunuma M Fau Narasimhan SD, Narasimhan Sd Fau Neumann-Haefelin E, Neumann-
- 617 Haefelin E Fau Sabatini DM, et al. TOR signaling and rapamycin influence longevity by
- 618 regulating SKN-1/Nrf and DAF-16/FoxO. (1932-7420 (Electronic))
- 619 14. Miller RA, Harrison De Fau Astle CM, Astle Cm Fau Fernandez E, Fernandez E Fau -
- 620 Flurkey K, Flurkey K Fau Han M, Han M Fau Javors MA, et al. Rapamycin-mediated lifespan
- increase in mice is dose and sex dependent and metabolically distinct from dietary restriction.
- 622 (1474-9726 (Electronic))
- 623 15. Juricic P, Lu Y-X, Leech T, Drews LF, Paulitz J, Lu J, et al. Long-lasting geroprotection from
- brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy.
- 625 Nature Aging. 2022;2(9):824-36 10.1038/s43587-022-00278-w.
- 626 16. Bitto A, Ito TK, Pineda VV, LeTexier NJ, Huang HZ, Sutlief E, et al. Transient rapamycin
- treatment can increase lifespan and healthspan in middle-aged mice. eLife. 2016;5:e16351
- 628 10.7554/eLife.16351.
- 629 17. Barnett BG, Wesselowski SR, Gordon SG, Saunders AB, Promislow DEL, Schwartz SM, et
- al. A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on
- 631 cardiac function of low-dose rapamycin in 17 healthy client-owned dogs. (2297-1769 (Print))
- 632 18. Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE, Lamming DW. Intermittent
- 633 Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice. (1758-535X
- 634 (Electronic))
- 635 19. Powers RW, 3rd, Kaeberlein M Fau Caldwell SD, Caldwell Sd Fau Kennedy BK,
- 636 Kennedy Bk Fau Fields S, Fields S. Extension of chronological life span in yeast by decreased
- 637 TOR pathway signaling. (0890-9369 (Print))
- 638 20. Colman RJ, Anderson Rm Fau Johnson SC, Johnson Sc Fau Kastman EK, Kastman Ek
- 639 Fau Kosmatka KJ, Kosmatka Kj Fau Beasley TM, Beasley Tm Fau Allison DB, et al. Caloric
- restriction delays disease onset and mortality in rhesus monkeys. (1095-9203 (Electronic))

- 641 21. Harrison DE, Strong R Fau Sharp ZD, Sharp Zd Fau Nelson JF, Nelson Jf Fau Astle CM,
- Astle Cm Fau Flurkey K, Flurkey K Fau Nadon NL, et al. Rapamycin fed late in life extends
- 643 lifespan in genetically heterogeneous mice. (1476-4687 (Electronic))
- 644 22. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, et al. Rapamycin, But Not
- Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice. The Journals
- of Gerontology: Series A. 2011;66A(2):191-201 10.1093/gerona/glq178.
- 647 23. Flynn JM, O'Leary Mn Fau Zambataro CA, Zambataro Ca Fau Academia EC, Academia
- 648 Ec Fau Presley MP, Presley Mp Fau Garrett BJ, Garrett Bj Fau Zykovich A, et al. Late-life
- rapamycin treatment reverses age-related heart dysfunction. (1474-9726 (Electronic))
- 650 24. Selvarani R, Mohammed S, Richardson A. Effect of rapamycin on aging and age-related
- diseases-past and future. Geroscience. 2021;43(3):1135-58 https://doi.org/10.1007/s11357-
- 652 020-00274-1.
- 25. Zhang Y, Zhang J, Wang S. The role of rapamycin in healthspan extension via the delay of
- organ aging. Ageing Res Rev. 2021;70:101376 https://doi.org/10.1016/j.arr.2021.101376.
- 655 26. RapAdmin. Breaking: 15% Healthy Lifespan improvement via Rapamycin seen in
- 656 Marmosets 2024 [Available from: https://www.rapamycin.news/t/breaking-15-healthy-
- 657 lifespan-improvement-via-rapamycin-seen-in-marmosets/14325.
- 658 27. Weston AD, Grossardt BR, Garner HW, Kline TL, Chamberlain AM, Allen AM, et al.
- Abdominal body composition reference ranges and association with chronic conditions in an
- age- and sex-stratified representative sample of a geographically defined American population.
- J Gerontol A Biol Sci Med Sci. 2024;79(4) https://doi.org/10.1093/gerona/glae055.
- 662 28. Hunter GR, Gower BA, Kane BL. Age related shift in visceral fat. Int J Body Compos Res.
- 663 2010;8(3):103-8
- 664 29. Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab
- 665 Care. 2004;7(4):405-10 https://doi.org/10.1097/01.mco.0000134362.76653.b2.
- 666 30. Whitaker KM, Choh AC, Lee M, Towne B, Czerwinski SA, Demerath EW. Sex differences
- in the rate of abdominal adipose accrual during adulthood: the Fels Longitudinal Study. Int J
- Obes (Lond). 2016;40(8):1278-85 https://doi.org/10.1038/ijo.2016.48.

- 669 31. Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, et al. Change in bone
- 670 mineral density as a function of age in women and men and association with the use of
- antiresorptive agents. CMAJ. 2008;178(13):1660-8 https://doi.org/10.1503/cmaj.071416.
- 672 32. Alswat KA. Gender disparities in osteoporosis. J Clin Med Res. 2017;9(5):382-7
- 673 https://doi.org/10.14740/jocmr2970w.
- 674 33. Mikkola TM, Kautiainen H, von Bonsdorff MB, Salonen MK, Wasenius N, Kajantie E, et al.
- Body composition and changes in health-related quality of life in older age: a 10-year follow-up
- of the Helsinki Birth Cohort Study. Qual Life Res. 2020;29(8):2039-50
- 677 https://doi.org/10.1007/s11136-020-02453-1.
- 678 34. Chlabicz M, Dubatowka M, Jamiolkowski J, Sowa P, Lapinska M, Raczkowski A, et al.
- Subjective well-being in non-obese individuals depends strongly on body composition. Sci Rep.
- 680 2021;11(1):21797 https://doi.org/10.1038/s41598-021-01205-6.
- 681 35. Lin H, Salech F, Lim A, Vogrin S, Duque G. The effect of rapamycin and its analogues on
- age-related musculoskeletal diseases: a systematic review. Aging Clin Exp Res.
- 683 2022;34(10):2317-33 https://doi.org/10.1007/s40520-022-02190-0.
- 684 36. den Hartigh LJ, Goodspeed L, Wang SA, Kenerson HL, Omer M, O'Brien KD, et al. Chronic
- oral rapamycin decreases adiposity, hepatic triglycerides and insulin resistance in male mice fed
- a diet high in sucrose and saturated fat. Exp Physiol. 2018;103(11):1469-80
- 687 https://doi.org/10.1113/EP087207.
- 688 37. Konopka AR, Lamming DW, Investigators RP, Investigators E. Blazing a trail for the
- clinical use of rapamycin as a geroprotecTOR. Geroscience. 2023;45(5):2769-83
- 690 https://doi.org/10.1007/s11357-023-00935-x.
- 691 38. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. mTOR
- 692 inhibition improves immune function in the elderly. (1946-6242 (Electronic))
- 693 39. Mannick JB, Morris M, Hockey H-UP, Roma G, Beibel M, Kulmatycki K, et al. TORC1
- 694 inhibition enhances immune function and reduces infections in the elderly. Science
- 695 Translational Medicine. 2018;10(449):eaaq1564 10.1126/scitranslmed.aaq1564.

- 696 40. Mannick JB, Teo G, Bernardo P, Quinn D, Russell K, Klickstein L, et al. Targeting the
- 697 biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b
- and phase 3 randomised trials. (2666-7568 (Electronic))
- 699 41. Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, et al. TORC1
- inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med.
- 701 2018;10(449) https://doi.org/10.1126/scitranslmed.aaq1564.
- 702 42. Walters HE, Cox LS. mTORC inhibitors as broad-spectrum therapeutics for age-related
- 703 diseases. Int J Mol Sci. 2018;19(8) https://doi.org/10.3390/ijms19082325.
- 704 43. Viscomi MT, D'Amelio M, Cavallucci V, Latini L, Bisicchia E, Nazio F, et al. Stimulation of
- autophagy by rapamycin protects neurons from remote degeneration after acute focal brain
- 706 damage. Autophagy. 2012;8(2):222-35 10.4161/auto.8.2.18599.
- 707 44. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
- 708 Conceptual framework and item selection. (0025-7079 (Print))
- 709 45. Riddle DL, Perera RA. The WOMAC pain scale and crosstalk from co-occurring pain sites
- 710 in people with knee pain: A causal modeling study. Phys Ther. 2020;100(10):1872-81
- 711 https://doi.org/10.1093/pti/pzaa098.
- 712 46. Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, et al. Oral
- 713 mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on
- 714 pathobiology and impact on clinical practice. Cancer Med. 2016;5(8):1897-907
- 715 https://doi.org/10.1002/cam4.761.
- 716 47. Lee DJW, Hodzic Kuerec A, Maier AB. Targeting ageing with rapamycin and its
- 717 derivatives in humans: a systematic review. Lancet Healthy Longev. 2024;5(2):e152-e62
- 718 https://doi.org/10.1016/S2666-7568(23)00258-1.
- 719 48. Harinath G, Lee V, Nyquist A, Moel M, Wouters M, Hagemeier J, et al. The bioavailability
- of compounded and generic rapamycin in normative aging individuals: A retrospective study
- 721 and review with clinical implications. MedRxiv. 2024
- 722 https://doi.org/10.1101/2024.08.12.24311432.

- 723 49. Patocka J, Kuca K, Oleksak P, Nepovimova E, Valis M, Novotny M, et al. Rapamycin: Drug
- 724 Repurposing in SARS-CoV-2 Infection. Pharmaceuticals (Basel). 2021;14(3)
- 725 https://doi.org/10.3390/ph14030217.
- 726 50. Singla A, Harun N, Dilling DF, Merchant K, McMahan S, Ingledue R, et al. Safety and
- 727 efficacy of sirolimus in hospitalised patients with COVID-19 pneumonia. Respir Investig.
- 728 2024;62(2):216-22 https://doi.org/10.1016/j.resinv.2023.12.009.
- 729 51. Bischof E, Siow RC, Zhavoronkov A, Kaeberlein M. The potential of rapalogs to enhance
- 730 resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. Lancet Healthy
- 731 Longev. 2021;2(2):e105-e11 https://doi.org/10.1016/S2666-7568(20)30068-4.
- 732 52. Lv X, Cai J, Li X, Wang X, Ma H, Heianza Y, et al. Body composition, lifestyle, and
- 733 depression: a prospective study in the UK biobank. BMC Public Health. 2024;24(1):393
- 734 https://doi.org/10.1186/s12889-024-17891-6.
- 735 53. United States. Public Health Service. Office of the Surgeon General. 6 Determinants of
- bone health. Bone health and osteoporosis: a report of the Surgeon General. Rockville, Md.:
- 737 U.S. Dept. of Health and Human Services, Public Health Service, Office of the Surgeon General;
- 738 2004. p. xxxii, 404 p.

750

751

- 739 54. Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY).
- 740 2019;11(19):8048-67 https://doi.org/10.18632/aging.102355.
- 741 55. Puts MT, Toubasi S, Atkinson E, Ayala AP, Andrew M, Ashe MC, et al. Interventions to
- 742 prevent or reduce the level of frailty in community-dwelling older adults: a protocol for a
- scoping review of the literature and international policies. BMJ Open. 2016;6(3):e010959
- 744 https://doi.org/10.1136/bmjopen-2015-010959.
- 745 56. Apostolo J, Cooke R, Bobrowicz-Campos E, Santana S, Marcucci M, Cano A, et al.
- 746 Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: a
- 747 systematic review. JBI Database System Rev Implement Rep. 2018;16(1):140-232
- 748 https://doi.org/10.11124/JBISRIR-2017-003382.

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

Figure Legends Figure 1. Effects of rapamycin use on changes in measures of body composition. Notable trends of change in body composition from baseline to 48 weeks were observed between treatment groups for all subjects (a). Analysis of changes in body composition measures within sex revealed that bone mineral content improved significantly for men taking 10mg rapamycin (b) as did lean tissue mass for females taking 10mg rapamycin (c). *p <0.05, **p ≤ 0.005 Figure 2. Heterogeneity in rapamycin response reveals differential patterns of effects. Within all study arms, individual participants showed marked improvement and decline for each measure of body composition (a). A greater percentage of individuals in the improvement group were rapamycin users (b), with no specific bias in response across all measures by sex (c). Similar trends were observed for measures of VAT (d), however, BMC (e), and LTM (f) showed sex-specific improvement and decline. Figure 3. Rapamycin response categorized by Benefit Scores revealed biological change differences by response type. Improvements in VAT correlated with improvements on BMC and LTM, as well as with improved weight and BMI (a). A "Benefit Score" was computed for users based on summary scores of improvement or decline on each body composition measure evaluated by DEXA, which was significantly associated with rapamycin use (b). Separation of Benefit Scores by rapamycin dose and sex revealed a pronounced female benefit bias, with only improvement for all female rapamycin users (c). Subsequent analysis of gut health and blood biomarkers by benefit score revealed significant changes in measures of gut dysbiosis, immune readiness (d), and LDL levels (e) between high and low Benefit Scores, with greater magnitude of beneficial change for rapamycin users than placebo. Figure 4. Effects of rapamycin use on quality of life and frailty. Quality of life measures from the SF-36 showed improvements across most measures for female rapamycin users (a), with statistically significant improvements in scores of pain, social functioning, and overall quality of life. Male rapamycin users showed only trends of improvement for many measures, particularly

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

for the 5mg cohort (b). Similar patterns were seen for frailty measures from the WOMAC scale, with female rapamycin users showing improvements across most measures, and significant improvements in pain and overall frailty (c). In contrast, male rapamycin users did not show improvements on WOMAC scores relative to controls (d). Supplementary Figure S1. PEARL trial design and participant health scores. Schematic of trial enrollment, participant screening, randomization, and followup (a), and a summary of all participants health scores (b) highlighting significant baseline health of participants in this study. Supplementary Figure S2. Adverse events and types for PEARL participants. A summary of adverse event types by trial arm showed no rapamycin-specific adverse event patterns (a). Further investigation of adverse event types revealed similar effects for all trial arms, with the exception of a higher proportion of gastrointestinal events reported for rapamycin users than controls (b). Supplementary Figure S3. Effects of rapamycin use on sex-specific changes in measures of body composition over time. Change in body composition measures at the study midpoint (24 weeks) showed evidence of some measure of change (a) that largely stabilized to the patterns reported after 48 weeks. Change at 48 weeks of VAT, and of BMC in females and LTM in males did not show statistically significant improvements for rapamycin users relative to controls (b). Supplementary Figure S4. Heterogeneity of rapamycin response in body composition measures. Within trial arms, notable differences in participant responses were observed across all measures, with sex-specific differences in proportion of participants improving or declining for most measures. Supplementary Figure S5. Changes in blood biomarkers in response to rapamycin use. While no significant differences in biomarkers were outside the healthy reference range after 48

weeks, significant differences between treatment and control groups were observed for mean change in corpuscular hemoglobin (MCH) and mean platelet volume (MPV), and for the 10 mg rapamycin group in chloride levels, carbon dioxide levels, and mean corpuscular volume (MCV), and patients in the 5 mg rapamycin treatment group in platelets (a). No statistically significant changes were seen for other biomarkers (b). Supplementary Figure S6. Effects of rapamycin use on quality of life and frailty measures across groups. After 48 weeks of treatment most SF-36 scores of perceived Quality of Life improved in all groups (a), as did WOMAC scores of frailty (b).

839 Tables

Table 1: Baseline demographics and blood safety markers								
	5 mg	10 mg	Placebo	F(df1, df2)	p-value			
	N=40	N=36	N=39					
	Mean (SD)	Mean (SD)	Mean (SD)					
Age (years)	61.2 (7.6)	62.4 (9.1)	62.6 (6.6)	0.425(2, 112)	0.655			
Sex (Female) N (%)	17 (42.5)	9 (25.0)	15 (38.5)	$\chi^2=2.732(2)$	0.255			
Height (cm)	171.9 (10.0)	176.2 (9.0)	175.0 (9.1)	1.940(2, 101)	0.149			
Weight (kg)	75.6 (15.3)	80.1 (13.6)	75.2 (14.5)	1.263(2, 105)	0.287			
BMI (kg/m²)	25.2 (3.5)	25.6 (3.3)	24.3 (3.0)	1.407 (2, 100)	0.250			
Glucose (mg/dL)	90.9 (3.5)	92.1 (8.8)	91.5 (11.1)	0.160(2, 112)	0.852			
LDL cholesterol (mg/dL)	107.8 (34.4)	104.3 (39.5)	115.1 (32.4)	0.921(2, 112)	0.401			
Non-HDL cholesterol	119.4 (37.4)	121.6 (43.5)	134.2 (34.5)	1.683(2, 112)	0.191			
(mg/dL)								
Triglycerides (mg/dL)	86.2 (32.4)	90.0 (39.8)	92.8 (45.8)	0.280(2, 112)	0.756			
HbA1c (%)	5.2 (0.2)	5.3 (0.2)	5.3 (0.3)	3.418(2, 106)	0.036*			
Insulin (uIU/mL)	5.8 (5.2)	6.1 (4.2)	5.0 (3.2)	0.528(2, 110)	0.528			
ALT (U/L)	22.1 (10.8)	23.4 (9.0)	22.4 (12.9)	0.141(2, 112)	0.869			
AST (U/L)	22.7 (7.2)	23.4 (5.3)	22.6 (6.7)	0.154(2, 112)	0.857			
BUN (mg/dL)	16.8 (4.9)	15.8 (2.9)	16.3 (4.4)	0.487(2, 112)	0.616			
Creatinine (mg/dL)	0.9 (0.2)	1.0 (1.2)	1.0 (0.3)	1.045(2, 112)	0.355			
eGFR (mL/min/1.73m²)	85.4 (14.1)	83.0 (10.8)	79.1 (15.3)	2.007(2, 108)	0.139			

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SD: standard deviation.

Groups were compared using Analysis of Variance and post-hoc independent t-test. p < 0.05.

Table 2: Self-reported adverse events during study period						
	5 mg	10 mg	Placebo			
Cardiovascular						
-Cardiological event	-	-	1 (2.6%) 1			
-Discomfort/Tightness in chest	1 (2.5%) 1	-	-			
Gastrointestinal						
-Lower gastrointestinal symptoms	4 (10%) 5	6 (16.7%) 9	3 (7.7%) 3			
-Upper and lower gastrointestinal symptoms	3 (7.5%) 3	1 (2.8%) 2	1 (2.6%) 1			
-Upper gastrointestinal symptoms	2 (5%) 5	3 (8.3%) 4	-			
Musculoskeletal and Orthopedic						
-Musculoskeletal pain	10 (25%) 19	12 (33.3%) 20	11 (28.2%) 20			
-Deep tissue injury (closed)	1 (2.5%) 2	-	1 (2.6%) 1			
-Musculoskeletal/Orthopedic injury (closed)	1 (2.5%) 1	-	1 (2.6%) 1			
Neurological						
-Altered spatial orientation	1 (2.5%) 1	3 (8.3%) 7	2 (5.1%) 3			
-Cognitive decline	-	1 (2.8%) 1	-			
-Neuromuscular symptoms	-	1 (2.8%) 1	2 (5.1%) 2			
Oral and Dental						
-Mouth sores	3 (7.5%) 4	6 (16.7%) 14	6 (15.4%) 27			
-Dental symptoms	2 (5%) 3	2 (5.6%) 2	1 (2.6%) 1			
Respiratory						
-Cold/Flu/Sinus symptoms	23 (57.5%) 35	19 (52.8%) 29	22 (56.4%) 33			
-Respiratory symptoms	1 (2.5%) 2	-	-			
Sensory						
-Auditory perception symptoms	2 (5%) 2	3 (8.3%) 3	2 (5.1%) 2			
-Visual perception symptoms	1 (2.5%) 1	1 (2.8%) 1	-			
Skin and Wound						
-Superficial wound/Skin irritation	6 (15%) 8	7 (19.4%) 11	9 (23.1%) 12			
-Deep wound (opened)	-	-	2 (5.1%) 2			
-Skin bacterial/fungal infection	1 (2.5%) 1	-	2 (5.1%) 2			
Urinary, Kidney, and Reproductive						
-Kidney/Urinary symptoms	4 (10%) 5	2 (5.6%) 2	2 (5.1%) 2			

-Menopausal symptoms	1 (2.5%) 1	1 (2.8%) 1	2 (5.1%) 2
Other			
-Erectile dysfunction	-	1 (2.8%) 1	-
-Malaise	3 (7.5%) 11	2 (5.6%) 2	1 (2.6%) 1
-Eye infection/disorder	1 (2.5%) 1	1 (2.8%) 1	1 (2.6%) 1
-Mental Health Symptoms	1 (2.5%) 1	1 (2.8%) 1	1 (2.6%) 1
-Pain (not otherwise specified)	1 (2.5%) 1	1 (2.8%) 1	1 (2.6%) 1
-Sleep disturbances	-	1 (2.8%) 1	-
Chronic Issue Flare	12 (30%) 23	13 (36.1%) 28	10 (25.6%) 14
Chronic Issue Severity	4 (10%) 4	4 (11.1%) 6	4 (10.3%) 12

^{*}Includes all reported events by the cohort. Some participants had multiple events or experienced the same events multiple times. Adverse events reported as: n participants (%) n events. Chronic issue flare: participants entered the PEARL trial with a chronic ailment which improved or stayed the same during the trial. Chronic issue severity: participants entered the PEARL trial with a chronic ailment that worsened during the trial.

Table 3: Dexa baseline output and change after 48 weeks, stratified by sex

Baseline							
Values for Females, <i>Males</i>				Changes by sex		Changes by group	
	5 mg	10 mg	Placebo	F(df1, df2)†	p-value†	F(df1, df2) ‡	p-value ‡
	500.6	407.0	518.2	F(2, 37) = 0.231	0.705		
Visceral adipose	(449.7)	(346.2)	(321.5)	F(2, 37) = 0.231	0.795	F(5, 107) =	.
tissue mass (g)	1321.2	1203.7	1084.3	-41		5.426	< 0.001
	(995.0)	(810.4)	(690.4)	F(2, 70) = 0.470	0.627		
	2174.4	2422.7	2196.6	r/2 2r\ - 1 00r	0.167		
Bone mineral	(245.6)	(490.6)	(239.8)	F(2, 35) = 1.885	0.167	F(5, 101) =	
content (g)	3059.9	3048.9	3243.7		22.304	< 0.001 304	
	(492.9)	(397.4)	(529.9)	F(2, 66) = 1.242	0.295		
	39313.1	41231.8	38983.8	F/2 27\ 0.400	0.640		
Lean tissue	(5098.6)	(8112.7)	(3769.5)	F(2,37) = 0.488 0.618	F(5, 106) =	< 0.001	
mass (g)	58290.8	58864.5	59950.8		44.559		
	(6084.4)	(7178.5)	(8154.6)	F(2, 69) = 0.317	0.729		
	1.1210	1.1951	1.1035	E/2 2E\ = 1 E27	0.220		
Bone Mineral	(0.1182)	(0.1799)	(0.0838)	F(2, 35) = 1.537	0.229	0.229 F(5, 103) =	
Density (g/cm2)	1.2558	1.3006	1.3397	5/50) 1 000	0.450	8.983 0.159	< 0.001
	(0.1750)	(0.1228)	(0.1341)	F(68) = 1.890	0.159		
Change from base	eline – 48 w	eeks					
	-29.3	-6.1	50.7 (69.3)	F(2,34.546) =	0.287		
Visceral adipose	(170.6)	(116.2)	30.7 (03.3)	1.294		F(2, 203.934)	0.427
tissue mass (g)	-48.6	19.2	26.9	F(2. 127.416) =	0.70	= 0.854	0.427
	(201.0)	(277.4)	(362.6)	0.329	0.72		

Bone mineral	-19.8 (64.4)	-50.6 (106.8)	-23.1 (82.0)	F(2, 43.111) = 0.251	0.779	F(2, 193.245)	0.012
content (g)	-41.7 (95.2)	45.2 (93.3)	-0.7 (100.6)	F(2, 70.240) = 2.249	0.113	= 4.489	
Lean tissue	-60.6 (1613.8)	1939.7 (1998.9)	-298.1 (1191.1)	F(1,70.369) = 1.022	0.004	F(2, 206.447)	0.005
mass (g)	-68.6 (3034.7)	-6.0 (2421.2)	-525.1 (2138.6)	F(2, 80.616) = 0.112	0.894	= 5.439 <i>4</i>	0.003
Bone Mineral	-0.0114 (0.0195)	-0.0100 (0.0325)	-0.0021 (0.0332)	F(2,43.316) = 1.461	0.243	F(2, 163.750)	0.191
Density (g/cm2)	0.0463 (0.2108)	0.0046 (0.0361)	-0.0012 (0.0267)	F(2, 109.733) = 1.006	0.369	= 1.673	0.131

⁸⁵⁸ Values provided as mean (standard deviation). Groups were compared using Analysis of Variance (baseline)
859 and linear mixed effects model (change from week 0 through 48) by sex and group.
860

Table 4: Baseline SF-36 and WOMAC and absolute change at 48 weeks, stratified by sex

	Women			Men			
	5 mg	10 mg	Placebo	5 mg	10 mg	Placebo	
<u>Baseline</u>							
SF-36							
- Physical functioning	95.3 (6.2)	96.1 (4.2)	93.0 (10.7)	94.6 (8.3)	95.6 (9.8)	95.5 (8.7)	
- Physical role limitations	92.7 (14.7)	94.4 (11.0)	83.3 (32.3)	94.6 (21.3)	95.4 (12.1)	90.9 (23.8)	
- Emotional role limitations	90.2 (22.9)	100.0 (0.0)	97.8 (8.6)	85.5 (26.3)	97.5 (8.9)	89.4 (23.9)	
- Energy/fatigue	62.4 (21.3)	65.6 (14.5)	67.7 (22.4)	66.5 (16.9)	73.5 (12.7)	69.6 (13.3)	
- Emotional well-being	76.5 (14.6)	76.9 (12.0)	82.4 (10.1)	75.7 (14.3)	85.9 (8.7)	80.4 (11.5)	
- Social functioning	92.7 (11.7)	84.7 (27.1)	92.5 (11.4)	92.4 (15.0)	96.3 (8.4)	94.9 (10.7)	
- Pain	82.9 (9.9)	74.4 (20.3)	82.3 (18.5)	84.7 (14.7)	87.7 (13.1)	79.4 (18.0)	
- General health	77.4 (19.5)	75.6 (17.9)	76.3 (21.2)	75.7 (15.0)	85.0 (15.3)	76.1 (18.3)	
- Physical health score	87.1 (9.5)	85.1 (9.9)	83.8 (18.0)	87.4 (12.0)	90.9 (7.8)	85.5 (14.1)	
- Mental health score	80.4 (12.1)	81.8 (8.4)	85.1 (10.5)	80.0 (14.0)	88.3 (6.9)	83.6 (11.9)	
- Aggregate score	83.7 (10.0)	83.5 (7.3)	84.4 (13.5)	83.7 (10.9)	89.6 (6.3)	84.5 (11.3)	
WOMAC							
- Total score (0-96)	28.6 (5.5)	28.7 (6.3)	31.9 (12.6)	29.0 (6.7)	28.2 (8.3)	30.4 (8.1)	
- Pain score (0-20)	6.4 (1.8)	6.4 (2.8)	6.7 (2.4)	6.5 (2.2)	6.2 (2.3)	6.1 (1.6)	
- Stiffness score (0-8)	3.4 (1.3)	3.2 (1.1)	3.5 (1.6)	2.8 (1.1)	2.7 (1.1)	3.5 (1.2)	
- Physical function score (0-68)	18.8 (3.3)	19.0 (4.6)	21.7 (9.0)	19.7 (4.1)	19.3 (5.4)	20.8 (5.9)	
Change baseline - 48 weeks							

SF-36							
- Physical functioning	+0.6 (4.8)	0.0 (6.0)	+0.4 (4.1)	-3.3 (15.3)	-1.6 (6.3)	-0.5 (9.7)	
- Physical role limitations	+3.1 (15.5)	+3.1 (8.8)	+5.4 (35.6)	-7.1 (28.7)	-4.0 (22.5)	+0.0 (30.9)	
- Emotional role	+4.2 (16.7)	-4.2 (11.8)	+2.4 (8.9)	+4.8 (33.8)	0.0 (9.6)	+9.3 (25.1)	
limitations	+4.2 (10.7)	-4.2 (11.0)	+2.4 (0. <i>3)</i>	+4.0 (33.0)	0.0 (9.0)	13.3 (23.1)	
- Energy/fatigue	+10.0 (17.4)	+9.4	+2.9 (13.7)	+3.0 (12.7)	+2.6 (8.8)	+0.3 (9.0)	
	+10.0 (17.4)	(12.9)	+2.9 (15.7)	+5.0 (12.7)	+2.0 (0.0)	10.3 (3.0)	
- Emotional well-being	+5.8 (14.2)	+5.0 (9.5)	+4.6 (9.1)	+5.2 (10.4)	+0.8 (5.8)	+3.3 (7.6)	
- Social functioning	+3.9 (10.9)	+12.5	+1.8 (12.8)	+2.5 (15.5)	+1.0 (11.4)	+2.1 (8.8)	
	+5.5 (10.5)	(24.1)	+1.0 (12.0)	+2.5 (15.5)	+1.0 (11.4)		
- Pain	+7.0 (11.9)	+14.7	+1.8 (9.1)	-1.2 (17.8)	-0.9 (8.0)	+1.5 (15.2)	
	+7.0 (11.9)	(13.9)	+1.0 (9.1)		-0.9 (8.0)	+1.5 (15.2)	
- General health	+5.3 (12.3)	+5.6	+3.9 (10.2)	+5.8 (8.8)	+2.4 (9.4)	-1.7 (13.0)	
	+3.3 (12.3)	(12.1)	+3.9 (10.2)	+3.8 (8.8)	+2.4 (3.4)	-1.7 (13.0)	
- Physical health score	+4.0 (8.0)	+5.9 (5.7)	+2.9 (11.5)	-2.4 (17.9)	-1.0 (7.6)	-0.2 (13.7)	
- Mental health score	+6.0 (11.4)	+5.7 (5.9)	+2.9 (7.7)	+4.8 (13.5)	+1.1 (5.3)	+3.7 (8.9)	
- Aggregate score	+5.0 (8.9)	+5.8 (4.6)	+2.9 (7.8)	+2.9 (10.3)	+0.0 (5.6)	+1.8 (8.7)	
WOMAC							
- Total score (0-96)	-2.3 (5.5)	-3.0 (6.2)	-1.1 (5.1)	-1.0 (4.7)	+2.0 (7.8)	-1.1 (6.6)	
- Pain score (0-20)	-0.9 (1.8)	-0.8 (2.9)	+0.4 (2.7)	-0.4 (1.7)	+0.6 (2.4)	-0.3 (1.1)	
- Stiffness score (0-8)	-0.7 (1.3)	-0.6 (1.2)	-0.5 (0.9)	-0.2 (1.1)	+0.2 (1.0)	-0.1 (1.2)	
- Physical function score	-0.6 (3.4)	-1.6 (5.2)	-1.0 (3.3)	-0.5 (2.7)	+1.2 (5.3)	-0.7 (5.6)	
(0-68)	-0.0 (3.4)	-1.0 (3.2)	-1.0 (3.3)	-0.3 (2.7)	11.2 (3.3)	-0.7 (3.0)	

SF-36: short form 36; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index. Values provided as mean (standard deviation).

Supplementary Table S1: Week 48 safety-related blood work assessment								
	5 mg	10 mg	Placebo	F(df1, df2)	p-value			
	N=38	N=33	N=34					
	Mean (SD) *	Mean (SD) *	Mean (SD) *					
Glucose (mg/dL)	91.3 (9.6)	91.8 (8.1)	89.7 (9.5)	F(2, 101) = 0.489	0.614			
LDL cholesterol (mg/dL)	107.9 (34.8)	96.2 (34.1)	103.5 (30.7)	F(2, 102) = 1.095	0.339			
Non-HDL cholesterol (mg/dL)	126.0 (37.6)	116.1 (38.4)	121.3 (32.5)	F(2, 101) = 0.647	0.526			
Triglycerides (mg/dL)	87.1 (33.2)	95.3 (52.1)	84.3 (36.0)	F(2, 102) = 0.659	0.520			
HbA1c (%)	5.2 (0.3)	5.3 (0.3)	5.3 (0.3)	F(2, 102) = 0.961	0.386			
Insulin (uIU/mL)	6.0 (4.7)	7.2 (4.2)	5.5 (3.2)	F(2, 100) = 1.566	0.214			
ALT (U/L)	20.1 (10.4)	25.0 (10.3)	22.0 (10.7)	F(2, 102) = 1.967	0.145			
AST (U/L)	21.7 (6.4)	24.6 (7.4)	23.0 (8.5)	F(2, 102) = 1.355	0.263			
BUN (mg/dL)	17.1 (3.6)	17.2 (3.9)	16.6 (3.9)	F(2, 102) = 0.277	0.759			
Creatinine (mg/dL)	0.9 (0.2)	0.9 (0.2)	1.0 (0.3)	F(2, 102) = 0.597	0.553			
eGFR (mL/min/1.73m²)	86.3 (13.6)	84.6 (12.3)	81.5 (15.6)	F(2, 98) = 1.026	0.362			

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SD: standard deviation. Groups were compared using Analysis of Variance. $^*p < 0.05$

872

Density (g/cm2)

(0.0097)

Supplementary Table S2: Baseline Dexa outcomes and absolute change after 48 weeks **Baseline Dexa Variable** 5 mg 10 mg **Placebo** F(df1, df2) p-value Visceral adipose 972.4 1016.2 866.5 F(2, 110) = 0.3560.701 (800.4)tissue mass (g) (900.2)(635.9)**Bone mineral** 2680.4 2901.6 2830.4 F(2, 104) = 1.2390.294 content (g) (598.6)(493.4)(676.6)Lean tissue mass (g) 50018.5 54715.6 51886.5 F(2, 109) = 1.5610.215 (11058.6)(10518.4)(12339.9)**Bone Mineral** 1.1996 1.2765 1.2488 F(2,106) = 2.0540.133 Density (g/cm2) (0.1422)(0.1644)(0.1662)**Dexa Variable** Change baseline - 48 weeks 5 mg 10 mg **Placebo** F(df1, df2) p-value **Visceral adipose** -39.9 +13.1 +35.3 F(2, 101.408) =0.379 tissue mass (g) (185.2)(290.8)(246.2)0.978 **Bone mineral** -31.9 +19.4 -8.7 (93.6) F(2,104.415) = 1.4030.250 content (g) (8.22)(104.3)Lean tissue mass (g) -66.0 +517.8 -444.6 F(2,126.996) = 1.1150.331 (2456.0)(2440.2)(1838.9)**Bone Mineral** 0.1593 8000.0 -0.0015 F(2,166.294) = 1.5960.552

Groups were compared using Analysis of Variance (baseline) and linear mixed effects model (change from week 0 through 48). Values provided as mean (standard deviation).

(00289)


0.0352)

Supplementary Table S3: Baseline SF-36 and WOMAC and absolute change at 48 weeks

	Baseline				48 weeks				
	5 mg	10 mg	Placebo	p-value	5 mg	10 mg	Placebo	p-value	
SF-36									
- Physical functioning	94.9	95.7	94.5	0.821	-1.6	-1.2 (6.1)	-0.2	0.754	
	(7.4)	(8.7)	(9.5)		(12.0)		(7.7)		
- Physical role limitations	93.8	95.1	87.8	0.263	-2.7	-2.3	+2.3	0.970	
	(18.6)	(11.7)	(27.4)		(24.1)	(20.1)	(32.6)		
- Emotional role	87.5	98.2	92.8	0.054	+4.5	-1.0	+6.3	0.401	
limitations	(24.7)	(7.7)	(19.5)		(27.4)	(10.2)	(19.7)		
- Energy/fatigue	64.8	71.5	68.8	0.209	+6.1	+4.2	+1.4	0.081	
	(18.7)	(13.4)	(17.3)		(15.2)	(10.2)	(11.2)		
- Emotional well-being	76.0	83.7	81.2	0.019	+5.4	+1.8	+3.9	0.479	
	(14.2)	(10.2)	(10.9)		(12.0)	(6.9)	(8.2)		
- Social functioning	92.5	93.4	93.9	0.896	+3.1	+3.8	+1.9	0.745	
	(13.5)	(15.7)	(10.9)		(13.5)	(15.8)	(10.6)		
- Pain	83.9	84.4	80.6	0.528	+2.4	+2.9	+1.6	0.682	
	(12.8)	(16.0)	(18.0)		(15.9)	(11.7)	(12.7)		
- General health	76.4	82.6	76.2	0.203	+5.6	+3.2	+0.8	0.014	
	(16.8)	(16.2)	(19.2)		(10.3)	(10.0)	(12.0)		
- Physical health score	87.2	89.5	84.7	0.254	+0.4	+0.6	+1.2	0.850	
	(10.9)	(8.6)	(15.5)		(14.6)	(7.7)	(12.7)		
- Mental health score	80.2	86.7	84.2	0.037	+5.3	+2.2	+3.4	0.385	
	(13.1)	(7.7)	(11.3)		(12.5)	(5.7)	(8.3)		
- Aggregate score	83.7	88.1	84.5	0.142	+3.8	+1.4	+2.3	0.335	
	(10.4)	(7.0)	(12.0)		(9.6)	(5.9)	(8.2)		
WOMAC									
- Total score (0-96)	28.8	28.3	31.0	0.325	-1.6 (5.0)	+0.8	-1.1	0.325	
	(6.2)	(7.8)	(10.0)			(7.7)	(5.9)		
- Pain score (0-20)	6.5 (2.0)	6.3 (2.4)	6.4 (2.0)	0.900	-0.6 (1.8)	+0.3	0.0 (1.9)	0.184	
						(2.5)			
- Stiffness score (0-8)	3.1 (1.2)	2.9 (1.1)	3.5 (1.4)	0.101	-0.4 (1.2)	0.0 (1.1)	-0.3	0.456	
							(1.1)		

- Physical function score	19.3	19.2	21.2	0.220	-0.6 (3.0)	+0.5	-0.8	0.614
(0-68)	(3.7)	(5.1)	(7.2)			(5.3)	(4.6)	

SF-36: short form 36; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index. Values provided as mean (standard deviation).



-2

48W


Time in Weeks


ow


0W

48W


Time in Weeks
























b






Time in Weeks

Time in Weeks





-15·


-10



Test







WOMAC Score Change

